nach oben

Inflammation Research

Erschienen in:

01.03.2012 | Original Research Paper

Vancomycin-loaded nano-hydroxyapatite pellets to treat MRSA-induced chronic osteomyelitis with bone defect in rabbits

verfasst von: Ji-Le Jiang, Yun-Fei Li, Tao-Lin Fang, Jian Zhou, Xi-Lei Li, Yi-Chao Wang, Jian Dong

Erschienen in: Inflammation Research | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Objective

To investigate nano-hydroxyapatite (nHA) pellets as carriers for vancomycin in the treatment of chronic osteomyelitis and bone defects due to methicillin-resistant Staphylococcus aureus (MRSA) strains.

Methods

Chronic osteomyelitis was induced in 45 New Zealand white rabbits. After 3 weeks (chronic infection), all animals were treated with debridement. The rabbits were divided into an experimental group (the bone was filled with vancomycin-loaded nHA pellets), a control group (the bone was filled with nHA pellets alone), and a blank group. The drug release profiles were determined in vitro and in vivo. X-rays, bone specimens, and microorganism cultures were used to evaluate the efficacy of the treatments.

Results

Following a rapid initial release into the circulation, the drug concentration remained effective in the osseous and soft tissues for 12 weeks after debridement. Within 3 months, all rabbits in the experimental group recovered from osteomyelitis without a recurrence of the infection and the bone defects were partially repaired, whereas the infection and bone defects persisted in the control and blank groups.

Conclusions

The results demonstrate that vancomycin-loaded nHA pellets successfully repair bone defects and control infection in MRSA-induced chronic osteomyelitis. In addition, nHA is an effective and safe controlled-release vancomycin carrier for chronic osteomyelitis with bone defects that is induced by MRSA.

Lazzarini L, Mader JT, Calhoun JH. Osteomyelitis in long bones. J Bone Joint Surg Am. 2004;86(10):2305–18.PubMed

Kinik H, Karaduman M. Cierny-Mader Type III chronic osteomyelitis: the results of patients treated with debridement, irrigation, vancomycin beads and systemic antibiotics. Int Orthop. 2008;32(4):551–8.PubMedCrossRef

Roeder B, Van Gils CC, Maling S. Antibiotic beads in the treatment of diabetic pedal osteomyelitis. J Foot Ankle Surg. 2000;39(2):124–30.PubMedCrossRef

Liu SJ, Wen-Neng SU, Lin SS, Chan EC. In vivo release of vancomycin from biodegradable beads. J Biomed Mater Res. 2002;63(6):807–13.PubMedCrossRef

Yamamoto T, Onga T, Marui T, Mizuno K. Use of hydroxyapatite to fill cavities after excision of benign bone tumours. Clinical results. J Bone Joint Surg Br. 2000;82(8):1117–20.PubMedCrossRef

Queiroz AC, Santos JD, Monteiro FJ. Porous HA scaffolds for drug releasing key engineering materials. Bioceramics. 2005;17:407–10. (Volumes 284–286).

Hasegawa M, Sudo A, Komlev VS, Barinov SM, Uchida A. High release of antibiotic from a novel hydroxyapatite with bimodal pore size distribution. J Biomed Mater Res B Appl Biomater. 2004;70(2):332–9.PubMedCrossRef

Ferraz MP, Mateus AY, Sousa JC, Monteiro FJ. Nanohydroxyapatite microspheres as delivery system for antibiotics: release kinetics, antimicrobial activity, and interaction with osteoblasts. J Biomed Mater Res A. 2007;81(4):994–1004.PubMed

Joosten U, Joist A, Gosheger G, Liljenqvist U, Brandt B, von Eiff C. Effectiveness of hydroxyapatite-vancomycin bone cement in the treatment of Staphylococcus aureus induced chronic osteomyelitis. Biomaterials. 2005;26(25):5251–8.PubMedCrossRef

10.

Webster TJ, Siegel RW, Bizios R. Enhanced surface and mechanical properties of nanophase ceramics to achieve orthopaedic/dental implant efficacy. Bioceramics. 2000;13:321–4.

11.

Liao J, Zhang L, Zuo Y, Wang H, Li J, Zuo Q, Li Y. Development of nanohydroxyapatite/polycarbonate composite for bone repair. J Biomater Appl. 2009;24(1):31–45.CrossRef

12.

Zhu W, Xiao J, Wang D, Liu J, Xiong J, Liu L, et al. Experimental study of nano-HA artificial bone with different pore sizes for repairing the radial defect. Int Orthop. 2009;33(2):567–71.PubMedCrossRef

13.

Zhu XL, Eibl O, Berthold C, Scheideler L, Geis-Gerstorfer J. Structural characterization of nanocrystalline hydroxyapatite and adhesion of pre-osteoblast cells. Nanotechnology. 2006;17(11):2711–21.CrossRef

14.

Meirelles L, Albrektsson T, Kjellin P, Arvidsson A, Franke-Stenport V, Andersson M, et al. Bone reaction to nano hydroxyapatite modified titanium implants placed in a gap-healing model. J Biomed Mater Res A. 2008;87(3):624–31.PubMed

15.

Boissard CI, Bourban PE, Tami AE, Alini M, Eglin D. Nanohydroxyapatite/poly(ester urethane) scaffold for bone tissue engineering. Acta Biomater. 2009;5(9):3316–27.PubMedCrossRef

16.

Cunniffe GM, Dickson GR, Partap S, Stanton KT, O’Brien FJ. Development and characterisation of a collagen nano-hydroxyapatite composite scaffold for bone tissue engineering. J Mater Sci Mater Med. 2010;21(8):2293–8.PubMedCrossRef

17.

Appleford MR, Oh S, Oh N, Ong JL. In vivo study on hydroxyapatite scaffolds with trabecular architecture for bone repair. J Biomed Mater Res A. 2009;89(4):1019–27.PubMed

18.

Shirtliff ME, Calhoun JH, Mader JT. Experimental osteomyelitis treatment with antibiotic-impregnated hydroxyapatite. Clin Orthop Relat Res. 2002;401:239–47.PubMedCrossRef

19.

Norden CW. Experimental chronic staphylococcal osteomyelitis in rabbits: treatment with rifampin alone and in combination with other antimicrobial agents. Rev Infect Dis. 1983;5(3):S491–4.PubMedCrossRef

20.

Murakami K, Minamide W, Wada K, Nakamura E, Teraoka H, Watanabe S. Identification of methicillin-resistant strains of staphylococci by polymerase chain reaction. J Clin Microbiol. 1991;29(10):2240–4.PubMed

21.

Smeltzer MS, Thomas JR, Hickmon SG, Skinner AR, Nelson CL, Griffith D, Parr TR Jr, Evans RP. Characterization of a rabbit model of staphylococcal osteomyelitis. J Orthop Res. 1997;15(3):414–21.PubMedCrossRef

22.

Lew DP, Waldvogel FA. Osteomyelitis. Lancet. 2004;364(9431):369–79.PubMedCrossRef

23.

Lamp KC, Friedrich LV, Mendez-Vigo L, Russo R. Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med. 2007;120(10):S13–20.PubMedCrossRef

24.

Perlroth JK, Kuo M, Tan J, Bayer AS, Miller LG. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med. 2008;168(8):805–19.PubMedCrossRef

25.

Obadia AGL, Daculsi G, Bouler JM. Calcium-deficient apatite: influence of granule size and consolidation mode on release and in vitro activity of vancomycin. Biomaterials. 2003;24:1265–70.PubMedCrossRef

26.

Sun Y, Zhang C, Jin D, Sheng J, Cheng X, Liu X, et al. Free vascularised fibular grafting in the treatment of large skeletal defects due to osteomyelitis. Int Orthop. 2010;34(3):425–30.PubMedCrossRef

27.

Ueng SW, Lee MS, Lin SS, Chan EC, Liu SJ. Development of a biodegradable alginate carrier system for antibiotics and bone cells. J Orthop Res. 2007;25(1):62–72.PubMedCrossRef

28.

Murugan R, Ramakrishna S. Aqueous mediated synthesis of bioresorbable nanocrystalline Hydroxyapatite. J Cryst Growth. 2005;274(1–2):209–13.CrossRef

Titel: Vancomycin-loaded nano-hydroxyapatite pellets to treat MRSA-induced chronic osteomyelitis with bone defect in rabbits
verfasst von: Ji-Le Jiang
Yun-Fei Li
Tao-Lin Fang
Jian Zhou
Xi-Lei Li
Yi-Chao Wang
Jian Dong
Publikationsdatum: 01.03.2012
Verlag: SP Birkhäuser Verlag Basel
Erschienen in: Inflammation Research / Ausgabe 3/2012
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-011-0402-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Vancomycin-loaded nano-hydroxyapatite pellets to treat MRSA-induced chronic osteomyelitis with bone defect in rabbits

Abstract

Objective

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Study of dexamethasone, baicalin and octreotide on brain injury of rats with severe acute pancreatitis

A20 and ABIN-3 possibly promote regression of trehalose 6,6′-dimycolate (TDM)-induced granuloma by interacting with an NF-kappa B signaling protein, TAK-1

The NLRP3 inflammasome is active but not essential in endotoxin-induced uveitis

The p38 mitogen-activated protein kinases modulate endothelial cell survival and tissue repair

Leishmania (Viannia) shawi purified antigens confer protection against murine cutaneous leishmaniasis

Severe neutrophil-mediated lung inflammation in myeloperoxidase-deficient mice exposed to zymosan

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin